German biotech firm working on COVID-19 vaccines not interested in takeover - (This is Money via NewsPoints Desk)

  • According to the Welt am Sonntag newspaper, BioNTech has recently been contacted by a number of industry players, but is not interested in a takeover, as reported in This Is Money.

  • Regulators in Germany recently approved human trials of a potential coronavirus vaccine that BioNTech is developing with Pfizer.

  • BioNTech chief executive Ugur Sahin said the company had been approached by several players in the industry, without saying what the subject of the approaches were.

  • "Takeovers are out of the question for the majority shareholders and for us anyway. Our vision is to build a biopharmaceutical company that addresses the medical needs of the 21st century," Sahin remarked.

To read more NewsPoints articles, click here.